Goldman Sachs Group Inc Pro Qr Therapeutics N.V. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.74 - $0.89 $1,395 - $1,678	-1,886 Reduced 1.18%	157,910 $117,000
Q3 2022 Nov 10, 2022	SELL	$0.74 - $0.89 $1,395 - $1,678	-1,886 Reduced 1.18%	157,910 $0
Q2 2022 May 14, 2024	BUY	$0.56 - $1.0 $89,485 - $159,796	159,796 New	159,796 $124,000
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.0 $345,037 - $616,139	-616,139 Reduced 79.41%	159,796 $124,000
Q1 2022 May 16, 2022	SELL	$0.9 - $8.39 $2.82 Million - $26.3 Million	-3,137,459 Reduced 80.17%	775,935 $702,000
Q4 2021 Feb 14, 2022	BUY	$6.58 - $8.44 $3.17 Million - $4.06 Million	481,325 Added 14.02%	3,913,394 $31.3 Million
Q3 2021 Nov 10, 2021	BUY	$5.16 - $8.47 $17.7 Million - $29.1 Million	3,432,069 New	3,432,069 $28.7 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $157M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.